Lv5
1350 积分 2023-10-24 加入
The state of the art in secondary pharmacology and its impact on the safety of new medicines
10天前
已完结
Physiological parameters in laboratory animals and humans
20天前
已完结
Further commentary: physiological parameters in laboratory animals and humans
20天前
已完结
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial
2个月前
已完结
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
2个月前
已完结
Traumatic brain injury: progress and challenges in prevention, clinical care, and research
2个月前
已完结
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
2个月前
已完结
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
2个月前
已完结
Levodopa pharmacokinetics. Alterations after benserazide, a decarboxylase inhibitor
2个月前
已关闭
Long-term l-Dopa pretreatment of mice: Central receptor subsensitivity or supersensitivity?
2个月前
已关闭
皖公网安备34019202002308
